Backed by cutting edge technology, an uncompromising focus on ease-of-use and dedicated customer service, Indica Labs’ software and services are being used to make vital discoveries in pathology labs and research organizations around the world.
+1 (505) 492 0979

Targeting Immuno-oncology Markers in the Tumor Microenvironment

Indica Labs / Events  / Targeting Immuno-oncology Markers in the Tumor Microenvironment

Targeting Immuno-oncology Markers in the Tumor Microenvironment

Available On-Demand

Hosted by Dr. Kate Lillard Tunstall, CSO, Indica Labs, and Dr. Travis Hollmann, Memorial Sloan Kettering Cancer Center on Thursday 16th November 2017 (8 am PDT | 11 am PDT | 4 pm BST).

This two-part webinar is a must see for anyone interested in spatially-resolved multiplexing for immuno-oncology or analysis of multi-spectral images, such as the PerkinElmer Vectra® 3 or Vectra® PolarisTM platforms.

In the first half hour, Dr. Kate Tunstall from Indica Labs will give a brief introduction to HALO’s multiplex and spatial analysis tools for immuno-oncology. She will give a short demonstration of HALO, including a new tool for fusing spectrally-unmixed field of view images captured from the PerkinElmer Vectra® 3 or PolarisTM platforms into whole tissue digital slides.

Following this introduction, we welcome our invited speaker, Dr. Travis Hollmann from Memorial Sloan Kettering Cancer Center. Dr. Hollmann will discuss multiplexing initiatives at Memorial Sloan Kettering Cancer Center, including: imaging platforms used by the center, utilizing fluorescent multiplexing in immuno-oncology, image analysis using HALO High-Plex, downstream of HALO High-Plex, and technical pitfalls, future platforms and community needs.

About Dr. Hollmann
Since the late 1990’s Dr. Hollmann has been a published immunology researcher focused on understanding both innate and adaptive mechanisms of the host response as they relate to human disease. After obtaining clinical training in anatomic pathology with subspecialty boards in dermatopathology, he returned to the immunology landscape with a focus on cutaneous tumor immunology. As a Melanoma Research Alliance young investigator and as pathologist for both melanoma and lung immunotherapy Stand Up to Cancer team science team awards, he has contributed to the correlation between tumor neoantigens and patient response to immunotherapeutics. More recently, as director of Advanced Immunomorphology Platforms at MSKCC, he runs the Parker Institute for Cancer Immunotherapy Pathology laboratory at MSKCC and co-directs the GE-MSKCC in situ single cell proteomics for cancer collaboration.